Development of Pandemic Vaccines: ERVEBO Case Study

Area of Science:

• Vaccinology
• Virology
• Public Health

Background:

• Preventative vaccines are vital for controlling infectious disease outbreaks and pandemics.
• Developing human vaccines is a complex, lengthy, and expensive process.
• The 2013-2016 Ebola virus disease (EVD) outbreak highlighted the urgent need for rapid vaccine development.

Purpose of the Study:

• To review the development program of the investigational *Zaire ebolavirus* (EBOV) vaccine candidate (rVSVΔG-ZEBOV-GP).
• To summarize safety, immunogenicity, and efficacy data for the EBOV vaccine.
• To highlight lessons learned for future pandemic vaccine development.

Main Methods:

• Review of the development program for the rVSVΔG-ZEBOV-GP vaccine.
• Summary of published and presented data on vaccine safety, immunogenicity, and efficacy.
• Analysis of ongoing research and development efforts.

Main Results:

• The rVSVΔG-ZEBOV-GP vaccine candidate was developed in five years through a public-private partnership.
• The vaccine received EMA and FDA approval as ERVEBO™ in December 2019.
• Data indicate favorable safety, immunogenicity, and efficacy profiles.

Conclusions:

• The rapid development of the EBOV vaccine demonstrates the feasibility of accelerated pandemic vaccine creation.
• Lessons learned from this program are applicable to the development of vaccines for future public health emergencies.
• Continued research and surveillance are essential for maintaining vaccine effectiveness and preparedness.